ArticleBritish journal of cancer2016
No association of CpG island methylator phenotype and colorectal cancer survival: population-based study.
Article in British journal of cancer, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Meta-Analysis of the Prognostic and Predictive Role of the CpG Island Methylator Phenotype in Colorectal Cancer.Disease markers · 2022Pooled it
- Global differences in the prevalence of the CpG island methylator phenotype of colorectal cancer.BMC cancer · 2019Pooled it
- Alcohol consumption and molecular subtypes of colorectal cancer: pooled observational and Mendelian randomization analyses.The American journal of clinical nutrition · 2026Observational
- Physical activity and molecular subtypes of colorectal cancer: a pooled observational analysis and Mendelian randomization study.JNCI cancer spectrum · 2025Observational
- Unraveling epigenetic heterogeneity across gastrointestinal adenocarcinomas through a standardized analytical framework.Molecular oncology · 2025Article
- Molecular subtypes of colorectal cancer in the era of precision oncotherapy: Current inspirations and future challenges.Cancer medicine · 2024Review
- Epigenetic insights into colorectal cancer: comprehensive genome-wide DNA methylation profiling of 294 patients in Korea.BMB reports · 2023Article
- Generalizable biomarker prediction from cancer pathology slides with self-supervised deep learning: A retrospective multi-centric study.Cell reports. Medicine · 2023Article
- Validation of the prognostic value of CD3 and CD8 cell densities analogous to the Immunoscore® by stage and location of colorectal cancer: an independent patient cohort study.The journal of pathology. Clinical research · 2023Article
- Swarm learning for decentralized artificial intelligence in cancer histopathology.Nature medicine · 2022Article
- Role of gene regulation and inter species interaction as a key factor in gut microbiota adaptation.Archives of microbiology · 2022Review
- Validation of Genetic Markers Associated with Survival in Colorectal Cancer Patients Treated with Oxaliplatin-Based Chemotherapy.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2022Observational
- Which patients to sample in clinical cohort studies when the number of events is high and measurement of additional markers is constrained by limited resources.Cancer medicine · 2020Article
- Differences in the immunosurveillance pattern associated with DNA mismatch repair status between right-sided and left-sided colorectal cancer.Cancer science · 2020Article
- Association Between Molecular Subtypes of Colorectal Tumors and Patient Survival, Based on Pooled Analysis of 7 International Studies.Gastroenterology · 2020Article
- Multiple gene promoter methylation and clinical stage in adjacent normal tissues: Effect on prognosis of colorectal cancer in Taiwan.Scientific reports · 2020Article
- Global burden of colorectal cancer: emerging trends, risk factors and prevention strategies.Nature reviews. Gastroenterology & hepatology · 2019Review
- The Evolving Biomarker Landscape for Treatment Selection in Metastatic Colorectal Cancer.Drugs · 2019Review
- A prognostic CpG score derived from epigenome-wide profiling of tumor tissue was independently associated with colorectal cancer survival.Clinical epigenetics · 2019Article
- Genome-wide DNA methylation differences according to oestrogen receptor beta status in colorectal cancer.Epigenetics · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPrevious studies have shown adverse effects of CpG island methylator phenotype (CIMP) on colorectal cancer (CRC) prognosis. However, sample sizes were often limited and only few studies were able to adjust for relevant molecular features associated with CIMP. The aim of this study was to investigate the impact of CIMP on CRC survival in a large population-based study with comprehensive adjustment.
methodsThe CIMP status and other molecular tumour features were analysed in 1385 CRC patients diagnosed between 2003 and 2010. Detailed information were obtained from standardised personal interviews and medical records. During follow-up (median: 4.9 years), we assessed vital status, cause of death and therapy details. Cox proportional hazard regression models were used to estimate adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) of survival after CRC.
resultsThe CIMP-H occurred more frequently in patients with older age, female gender, cancer in the proximal colon, BRAF mutation and microsatellite instability-high (MSI-H). However, CIMP status was not associated with CRC prognosis in CRC patients (HR=1.00; 95% CI=0.72-1.40 for overall survival; HR=0.96; 95% CI=0.65-1.41 for disease-specific survival) or in any of the subgroups. Although CIMP status was associated with the presence of MSI-H and BRAF mutation, the prognostic effects of MSI-H (HR=0.49; 95% CI=0.27-0.90) and BRAF mutation (HR=1.78; 95% CI=1.10-2.84) were independent of CIMP status. Similar benefit of chemotherapy was found for CRC outcomes in both the CIMP-low/negative group and the CIMP-high group.
conclusionsCpG island methylator phenotype was not associated with CRC prognosis after adjusting for other important clinical factors and associated mutations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.